Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA Plus Tislelizumab in EGFR-Mutant NSCLC
NCT07842887Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tretinoin in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Incidence and Severity of Adverse Events, Incidence of Dose-Limiting Toxicities at 28 days and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tretinoin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07842887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842887.